<DOC>
	<DOCNO>NCT00963872</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy total-body irradiation donor umbilical cord blood transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . PURPOSE : This phase I trial study safety donor umbilical cord blood transplant fludarabine phosphate , cyclophosphamide , total-body irradiation treat patient high-risk hematologic cancer ( close ) . The Phase II part trial study whether prim one two UCB unit C3a facilitate engraftment treated unit .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate , Cyclophosphamide , Total-Body Irradiation Treating Patients With High-Risk Hematologic Cancer</brief_title>
	<detailed_description>OUTLINE : - Nonmyeloablative preparative regimen : Patients receive fludarabine phosphate IV 1 hour day -6 -2 cyclophosphamide IV 2 hour day -6 . Patients undergo total-body irradiation day -1 . Some patient also receive anti-thymocyte globulin IV every 12 hour day -6 , -5 , -4 . - Umbilical cord blood ( UCB ) transplantation : Patients undergo unmanipulated UCB transplantation follow complement 3a fragment prim UCB transplantation day 0 . Treatment graft-vs-host disease prophylaxis also give . After completion study therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<mesh_term>Complement C3a</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Disease Criteria Acute Leukemias : Must remission morphology ( &lt; 5 % blast ) . Note cytogenetic relapse persistent disease without morphologic relapse acceptable . Also small percentage blast equivocal marrow regeneration vs. early relapse acceptable provide associate cytogenetic marker consistent relapse . ( See exclusion criterion detailed definition ) Acute myeloid leukemia : high risk CR1 ( evidence precede myelodysplastic syndrome ( MDS ) , high risk cytogenetics associated MDS complex karyotype , &gt; 2 cycle obtain complete remission ( CR ) erythroblastic megakaryocytic ) ; second great CR . Acute lymphoblastic leukemia/lymphoma : high risk CR1 evidence high risk cytogenetics ( e.g . ( 9 ; 22 , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangement ) &gt; 1 cycle obtain CR ; second great CR . Burkitt 's lymphoma CR2 subsequent CR Natural Killer cell malignancy Myeloproliferative syndromes/diseases : Chronic myelogenous leukemia ( CML ) chronic accelerate phase patient must fail intolerant Imatinib mesylate . EXCLUDED : CML refractory blast crisis , myelofibrosis , polycythemia vera , essential thrombocytosis . Myelodysplastic Syndrome : subtype include refractory anemia ( RA ) severe pancytopenia , high risk complex cytogenetics International Prognostic Scoring System ( IPSS ) ≥ intermediate2 ( Int2 ) . Blasts must less 5 % . If 5 % require therapy pretransplant reduce blast count ≤5 % . Patients receive single agent 5azacytidine , decitabine immunomodulating drug eligible . Largecell lymphoma , Hodgkin 's lymphoma multiple myeloma : patient chemotherapy sensitive disease fail ineligible autologous transplant . Patients eligible umbilical cord blood ( UCB ) transplantation evidence progressive disease image modality and/or biopsy . Persistent PET activity , though possibly relate lymphoma , IS NOT exclusion criterion absence computated tomography ( CT ) change size indicate progression . Largecell Hodgkin 's lymphoma progressive salvage therapy NOT eligible . Patients stable disease eligible transplantation large residual nodal mass &lt; 5 cm ( approximately ) . For patient respond precede therapy , large residual mass must represent 50 % reduction &lt; 7.5 cm ( approximately ) . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma , follicular lymphoma progress least two prior therapy . Patients bulky disease consider debulking chemotherapy transplant . Patients refractory disease eligible , unless bulky disease estimate tumor double time le one month . Patients stable disease eligible transplantation large residual nodal mass &lt; 5 cm ( approximately ) . For patient respond precede therapy , large residual mass must represent 50 % reduction &lt; 7.5 cm ( approximately ) . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy chemotherapy sensitive . Mantlecell lymphoma progressive salvage therapy NOT eligible . Patients stable disease eligible transplantation large residual nodal mass &lt; 5 cm ( approximately ) . For patient respond precede therapy , large residual mass must represent 50 % reduction &lt; 7.5 cm ( approximately ) . Umbilical Cord Blood Graft Selection Two UCB unit compose graft , unit must 46 HLAA , B , DRB1 antigen match , well 46 antigen match recipient . The combined cryopreserved nucleated cell dose 2 unit must ≥ 3 X 10^7/kg unit minimum cell dose 1.5 X 10^7/kg . UCB unit select accord common umbilical cord blood graft selection algorithm Performance Status adequate performance status define Karnofsky score ≥ 60 Age 18 70 year age ; patient ≥ 70 ≤ 75 year eligible comorbidity score ≤ 2 Organ Function Cardiac : Left ventricular ejection fraction &gt; 35 % ; absence decompensated congestive heart failure ; absence uncontrolled arrhythmia Pulmonary : DLCO &gt; 30 % predict ; absence O2 requirement Hepatic : ALT , AST , alkaline phosphatase bilirubin &lt; 5 x upper limit normal Renal : Creatinine ≤ 2 mg/dl ( patient creatinine &gt; 1.2 history renal dysfunction must calculate glomerular filtration rate ( GFR ) &gt; 40 mL/min/1.73m2 ) If recent mold infection e.g . Aspergillus must minimum 30 day appropriate treatment transplant infection control clear Infectious Disease . The following condition must meet : If prior myeloablative autologous transplant , must &gt; 3 month ≤ 12 month transplant OR receive least 2 cycle multiagent highly immunosuppressive chemotherapy ( i.e . induction acute leukemia ) within 3 month precede study . OR If neither prior myeloablative autologous transplant ≤ 12 month transplant receive least 2 cycle multiagent highly immunosuppressive chemotherapy ( i.e . induction acute leukemia ) within 3 month precede study , patient eligible long receive equine antithymocyte globulin part condition regimen . Patients available , medically suitable , 56/6 HLAA , B , DRB1 match sibling donor Patients eligible autologous transplantation Prior allogeneic transplant Acquired inherit bone marrow failure syndromes aplastic anemia Fanconi anemia Pregnant breast feed Evidence HIV infection know HIV positive serology Current uncontrolled serious infection Active central nervous system malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>